Sex-related differences in heart failure and beta-blockers

Heart Failure Reviews

Volumn 9, Issue 2, 2004, Pages 149-159

  Ghali, Jalal K ^a  

^a Cardiac Centers of Louisiana   (United States)

Author keywords

Beta blockers; Gender; Heart failure; Sex; Women

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CANDESARTAN; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IBOPAMINE; LISINOPRIL; LOSARTAN; METOPROLOL; MILRINONE; PIPERANOMETOZINE; PLACEBO; SPIRONOLACTONE; VALSARTAN;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED RELEASE FORMULATION; DRUG EFFICACY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PREVALENCE; SEX DIFFERENCE; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HEART FAILURE, CONGESTIVE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; SEX FACTORS; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 8444245522     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:HREV.0000046370.81174.94     Document Type: Article

References (69)

1. Robertson RM. Women and cardiovascular disease. Circulation 2001 103:2318-2320.
2. Julian DG, Wenger NK. Women and Heart Disease. Martin Dunitz Ltd 1997.
3. Ghali JK. A clinician's perspective on clinical trials. J Card Fail 2001;7:1-3.
4. Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol 1997:30:1417-1419.
5. Petrie MC, Dawson NF, Murdoch DR, Davie AP, McMurray JJV. Failure of women's hearts. Circulation 1999;2334-2341.
6. Hoppe BL, Hermann DD. Sex differences in the causes and natural history of heart failure. Current Cardiology Reports 2003;5:193-199.
7. Institute of Medicine. Exploring the Biological Contributions to Human Health: Does Sex Matter? Washington DC: National Academy Press, 2001.
8. Ni, H. Prevalence of self-reported heart failure among US adults: Results from the 1999 National Health Interview Survey. Am Heart J 2003 ;146:121-128.
9. Heart and Stroke Statistical Update. Dallas Tex: American Heart Association, 2003.
10. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002 347:1397-1402.
11. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-1562.
12. Koelling TM, Chen RS, Lubwama RN, L'Italien GJ, Eagle KA. The expanding national burden of heart failure in the United States: The influence of heart failure in women. Am Heart J 2004;147:74-78.
13. Senni M, Tribouilloy CM, Rodeheffer, et al. Congestive heart failure in the community. A study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998;98:2282-2289.
14. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients ≥65 years of age. Am J Cardiol 2001;87:413-419.
15. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol 1999;33:1948-1955.
16. Masoudi FA, Havranek EP, Smith G, et al. Gender, age and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003;41:217-223.
17. Mendes LA, Davidoff R, Cupples LA, et al. Congestive heart failure in patients with coronary artery disease: The gender paradox. Am Heart J 1997;134:207-212.
18. Carroll JD, Carroll EP, Feldman T, et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992;86:1099-1107.
19. Gerdts E, Zabalgoitia M, Björnstad H, Svendsen TL, Devereux RB. Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (The LIFE Study). Am J Cardiol 2001;87:980-983.
20. Litwin SE, Katz SE, Litwin CM, Morgan JP, Douglas PS. Gender differences in post infarction left ventricular remodeling. Cardiology 1999;91:173-183.
21. Gardner JD, Brower GL, Janicki JS. Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail 2002 8:101-107.
22. Douglas PS, Katz SE, Weinberg EO, Chen MH, Bishop SP, Lorell BH. Hypertrophic remodeling: Gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 1998 ;32:1118-1125.
23. Tamura T, Said S, Gerdes AM. Gender-related differences in myocyte remodeling in progression to heart failure. Hypertension 1999 33:676-680.
24. Adams KF, Dunlap SH, Sueta CA, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996;28:1781-1788.
25. Adams KF, Sueta CA, Gheorghiade M, et al. Gender differences in survival in advanced heart failure: Insights from the FIRST study. Circulation 1999;99:1816-1821.
26. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC. Metoprolol CR/XL in female patients with heart failure: Analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002;105:1585-1591.
27. Ghali JK, Krause-Steinrauf HJ, Adams KF, et al. Gender differences in advanced heart failure: Insights from the BEST study. J Am Coll Cardiol 2003;42:2128-2134.
28. Simon T, Mary-Krause M, Funck-Brentano C. Sex differences in the prognosis of congestive heart failure: Results from We cardiac insufficiency bisoprolol study (CIBIS II). Circulation 103:375-380.
29. DeMaria RD, Gavazzi A, Recalcati F, Baroldi G, DeVita C, Camerini R. Comparison of clinical findings in idiopathic dilated cardiomyopathy in women versus men. Am J Cardiol 1993;72:580-585.
30. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: The Framingham Study. N Engl J Med 1971 285:1442-1446.
31. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study (V-HEFT). N Engl J Med 1986 ;314:1547-1552.
32. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
33. Cohn J, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
34. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
35. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
36. Packer M, Carver JR, Rodeheffer RJ, et al. for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
37. Singh SN, Fletcher RD, Fisher SG, et al. for the survival trial of antiarrhythmic therapy in congestive heart failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
38. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer, Cropp AB, DeMets DL. Effect of Amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107-1114.
39. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997 134: 44-54.
40. Hamptom JR, van Veldhuisen DJ, Kleber FX, et al. for the Second Prospective Randomized Study of Ibopamine on mortality and efficacy (PRIME II) Investigators. Randomized study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997 349:971-977.
41. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997 ;336:525-533.
42. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
43. Cohn JN, Goldstein SO, Greenberg BH, et al. for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998 339:1810-1816.
44. CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomized trial of beta-blockade in heart failure. Lancet 1999;353:9-13.
45. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007.
46. Packer M, Poole-Wilson PA, Armstrong PW, et al. on behalf of the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-2318.
47. Pitt B, Zannad F, Remme WJ, et al. for the Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
48. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
49. The BEST Investigators. The beta-blocker evaluation of survival trial (BEST). N Engl J Med 2001;344:1659-1667.
50. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 345:1667-1675.
51. Packer M, Fowler MB, Roecker EB, et al. Effect of Carvedilol on the Morbidity of Patients with Severe Chronic Heart Failure. Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002;106:2194-2199.
52. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol OR Metoprolol European Trial (COMET): Randomized controlled trial. Lancet 2003;362(9377):7-13.
53. McMurray J, Ostergren J, Pfeffer M, et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: Baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003;5:261-270.
54. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002 347:1403-1411.
55. Hunt SA, Baker DW, Chin ME, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) 2001. (http://www.acc.org/clinical/guidelines/failure/hf_index.htm).
56. Heart Failure Society of America (HFSA) Practice Guidelines: HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail 1999;5:357-382.
57. Limacher MC, Yusuf S for the SOLVD Investigators. Gender differences in presentation, morbidity and mortality in the Studies Of Left Ventricular Dysfunction (SOLVD): A preliminary report. In: Wenger NK, Speroff L, Packard B, eds. Cardiovascular Health and Disease in Women. Greenwich, CT: LeJacq Communications, 1993:345-348.
58. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-1456.
59. Lindenfeld JA. Ghali JK, Krause-Steinrauf HJ, et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. J Am Coll Cardiol 2003;42:1238-1245.
60. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelial dependent flow-mediated vasodilation in post-menopausal women. Ann Intern Med 1994;121:936-941.
61. Weitz G, Elam M, Born J, et al. Postmenopausal estrogen administration suppresses muscle sympathetic nerve activity. J Clin Endocrinol Metab 2001;86:344-348.
62. Komesaroff PA, Esler MD, Sudhir K. Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. J Clin Endocrinol Metab 1999;84:606-610.
63. Nogawa N, Sumino H, Ichikawa S, et al. Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postmenopausal women with essential hypertension and normotensive postmenopausal women. Menopause 2001;8:210-215.
64. Ylikarkala O, Orpana A, Puolakka J, et al. Postmenopausal hormonal replacement decreases plasma levels of endothelin-I. J Clin Endocrinol Metab 1995;80:3384-3387.
65. Reis SE, Holubkov R, Young JB, et al. Estrogen is associated with improved survival in aging women with congestive heart failure: Analysis of the vesnarinone studies. J Am Coll Cardiol 2000 36:529-533.
66. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
67. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132:689-696.
68. Ghali JK, Piña IL, Gottlieb SS, et al. Metoprolol R/SL in femal patients with heart failure: Analysis of the experience in metoprolol extended-release randomized intervention trial in heart failure (MERIT-HF). Circulation 2002;105:1585-1591.
69. Luzier AB, Killian A, Wilton JH, et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamis in healthy volunteers. Clin Pharmacol Ther 1999;66:594-601.